BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Paul Capital Healthcare Commits $100 Million in Initial Funding to Phase III Development Company S.A.R.L Established to Assist in Management and Funding of Phase III Clinical Trials; Company Announces First Definitive Agreement


1/5/2010 6:32:49 AM

Bookmark and Share

NEW YORK, Jan. 5 /PRNewswire/ -- Paul Capital Healthcare today announced that it has agreed to provide up to $100 million to Phase III Development Company S.A.R.L ("P3D"), a company recently established to assist in the management and funding of clinical trials in the European Union. At the same time, P3D announced that it had entered into a definitive agreement with a major global pharmaceutical company to fund the label expansion of a currently approved therapeutic product. Under the terms of the agreement, P3D will assist in the management and funding of phase III clinical trials in additional indications for the product. In return, the pharmaceutical company will provide P3D with development and regulatory milestone payments related to the phase III trials, a percentage of certain out-licensed product royalties, and a percentage of the revenue it generates on the product once it is approved in the additional indications that are the subject of the clinical trials.

"By funding P3D, we can provide a truly novel means of assisting pharmaceutical companies seeking external financing and risk sharing in the development of their late stage drug pipelines. This is truly an important event in the healthcare product finance industry" said Ken Macleod, Ph.D., Partner in the London office of Paul Capital Healthcare. "For years, our industry has been looking for ways to make this type of collaboration work, and we now have the right win-win structure. Companies can now benefit by accessing risk capital to support a compelling growth opportunity while minimizing the impact on internal financial resources, and Paul Capital Healthcare through P3D has an opportunity to participate in a diversified pool of royalties, development milestones and revenue interests with the potential for exciting returns."

About Paul Capital Healthcare and Paul Capital

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.6 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $1 billion in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at www.paulcapitalhealthcare.com. Paul Capital manages nearly $7.3 billion in capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondary Funds and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.

Contact Information:

Media Inquiries/Lazar Partners Susan Rood Tel: +1-212-843-0210 Email: srood@lazarpartners.com

Stephanie Seiler Tel: +1-206-713-0124 Email: sseiler@lazarpartners.com

Paul Capital Healthcare Ken Macleod, Ph.D., Partner Tel: +44 (20) 7514 0754 Email: kmacleod@paulcap.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES